Active Biotech's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology
Lund, Sweden, September 20, 2011 - the Journal of Clinical Oncology (http://jco.ascopubs.org/content/early/recent) has published an article* presenting results from a controlled clinical Phase II study in 201 evaluable patients of Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project TASQ.
It was concluded in the study that TASQ significantly slowed disease progression and improved Progression Free Survival (PFS) in patients with metastatic castrate-resistant prostate cancer (CRPC), alongside an acceptable side effect profile. Six month progression free proportion of patients for TASQ and placebo treatment groups were 69% and 37%, respectively (p<0.0001), with a median PFS of 7.6 vs. 3.3 months (p=0.0042).
Enrollment of patients to a pivotal Phase III trial was initiated in March 2011. The Phase III study is a global, randomized, double-blind, placebo-controlled study in patients with metastatic CRPC. The aim of the study is to confirm TASQ's effect on the disease, with radiological PFS as the primary endpoint and overall survival as secondary endpoint. The planned study will include about 1,200 patients in more than 250 clinics.
Active Biotech AB (publ)
President & CEO
For further information, please contact
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
*Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Pili, R.,, Häggman, M., Stadler. W., Gingrich, J., Assikis, V., Björk, A., Nordle, Ö., Forsberg, G., Carducci, M., Armstrong, A.
Notes to editors
The development of TASQ is principally focused on the treatment of prostate cancer. TASQ is an antiangiogenic compound, meaning that it cuts off the supply of nutrients to the tumor. Studies have concluded that TASQ exhibits anti-tumor activity via inhibition of tumor angiogenesis. The up-regulation of the antiangiogenic protein thrombospondin-1 (TSP1) is a part of this mechanism. It was announced in December 2009 that the primary endpoint of the Phase II clinical study, to show a higher fraction of patients with no disease progression during the six-month period of treatment using TASQ, had been met.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for Systemic Sclerosis as well as RhuDexTM for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on September 20, 2011.
Posted: September 2011